Next Score View the next score

    Around the Region

    AVEO to cut 45 jobs, 17% of its staff

    AVEO Oncology, a Cambridge company looking to develop a treatment for advanced kidney cancer, has embarked on a “strategic restructuring” that will cut 45 positions, or 17 percent of the workforce, as well as eliminate 30 open positions.

    The reduction, unveiled Tuesday, is part of a program that is expected to save 100 million over the next three years, with $37 million in savings projected in 2013. After the restructuring, AVEO will have about 225 employees.

    The announcement was included in a press release about third-quarter earnings.


    Total collaboration revenue for the quarter was $1 million, compared with $3.6 million for the third quarter of 2011. AVEO said its net loss was $30.1 million, or basic and diluted net loss per share of 69 cents, compared with a net loss of $23.8 million, or basic and diluted net loss per share of 55 cents, a year earlier.

    Get Talking Points in your inbox:
    An afternoon recap of the day’s most important business news, delivered weekdays.
    Thank you for signing up! Sign up for more newsletters here

    In September, AVEO and the Japanese drug maker Astellas Pharma Inc. said they had submitted a new drug application to the Food and Drug Administration for tivozanib, a potential treatment for advanced kidney cancer.

    AVEO said Tuesday that it is now seeking collaborators to help develop ficlatuzumab, another cancer drug candidate.

    Chris Reidy